Диссертация (1174268), страница 19
Текст из файла (страница 19)
–Vol. 16:49. - Р. 210.51.Кнышов,Г.В.Причиныишемиимиокардапригипертрофическойкардиомиопатии / Г.В Кнышов, Е.К. Гогаева, К.В. Руденко [и др.] / Серце ісудини. - 2012. - № 4. - С. 15-20.52. Harjai, K.J. Ischemia and atherosclerotic coronary artery disease in patients withhypertrophic cardiomyopathy: a review of incidence, pathophysiological mechanisms,clinical implications and management strategies / K.J. Harjai, J. Cheirif, J.P.
Murgo //Coron Artery Dis. – 1996. – Vol.7. - № 3. – Р.183-7.53. Villa, A.D. Microvascular ischemia in hypertrophic cardiomyopathy: new insightsfrom high-resolution combined quantification of perfusion and late gadoliniumenhancement / A.D. Villa, E. Sammut, N. Zarinabad. [et al.] // J Cardiovasc MagnReson. - 2016. – Vol. 18:4. – P. 1-1154.
Demetrescu, C. Ischaemia as a cause of LVOT gradient reversal in HCM / C.Demetrescu, S.R. Haley, A. Baltabaeva // Echo Res Pract. - 2017. – Vol.4 - № 4. – Р.K31-K36.55. Harris, C. Hypertrophic obstructive cardiomyopathy / C. Harris, B. Croce, S.Munkholm-Larsen // Ann Cardiothorac Surg. – 2017. – Vol. 6. - № 4.
– Р. 429.56. Camici, P.G. Coronary microvascular dysfunction / P.G. Camici, F. Crea // N EnglJMed. – 2007 – Vol. 356. - № 8. – P. 830–40.57. Varnava, A.M. Relation between myocyte disarray and outcome in hypertrophiccardiomyopathy / A.M. Varnava, P.M. Elliott, N. Mahon [et al.] // Am J Cardiol. –2001. – Vol. 88. - № 3. – Р. 275-9.58. Cheng, S. LGE-CMR-derived texture features reflect poor prognosis in hypertrophiccardiomyopathypatients with systolic dysfunction: preliminary results / S.
Cheng, M.Fang, C. Cui [et al.] // Eur Radiol. – 2018. – Vol. 28. - № 11. - Р. 4615-4624.59. Mano, T. HCM / Mano T // Int Heart J. – 2018. – Vol. 59. - № 2. – Р. 243-244.12160. Weng, Z. Prognostic value of LGE-CMR in HCM: A meta-analysis / Z. Weng, J.Yao, R.H.
Chan [et al.] // JACC Cardiovasc Imaging . – 2016. - Vol. 9. - №12. - P.1392-402.61. Amano, Y. Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques,Findings, and Clinical Relevance / Y. Amano , M. Kitamura , H. Takano [et al.] // MagnReson Med Sci. – 2018. – Vol. 17. - № 2.
– Р. 120-131.62. He, D. Prognostic significance of late gadolinium enhancement on cardiac magneticresonance in patients with hypertrophic cardiomyopathy / D. He, M. Ye, L. Zhang [etal.] // Heart Lung. – 2018. - Vol. 47. - № 2 – Р. 122-126.63. Nojiri, A. Scoring of late gadolinium enhancement in cardiac magnetic resonanceimaging can predict cardiac events in patients with hypertrophic cardiomyopathy / A.Nojiri, K.
Hongo, M. Kawai [et al.] // J Cardiol. – 2011. - № 58. - Р. 253–260.64. Green, J.J. Prognostic value of late gadolinium enhancement in clinical outcomesfor hypertrophic cardiomyopathy / J.J. Green, J.S Berger, C.M Kramer [et al.] // JACCCardiovasc Imaging. – 2012. - Vol. 5. - № 4. –Р. 370-7.65. Bruder, O. Myocardial scar visualized by cardiovascular magnetic resonanceimaging predicts major adverse events in patients with hypertrophic cardiomyopathy /O.
Bruder, A. Wagner, C.J. Jensen [et al.] // J Am Coll Cardiol. – 2010. - Vol. 56. - №11. – Р. 875-87.66. Olivotto, I. Relevance of coronary microvascular flow impairment to long-termremodeling and systolic dysfunction in hypertrophic cardiomyopathy / I. Olivotto, F.Cecchi, R. Gistri [et al.] // J Am Coll Cardiol. - 2006.
– Vol. 47. - № 5. – Р. 1043-8.67. Cecchi, F. Coronary microvascular dysfunction and prognosis in hypertrophiccardiomyopathy / F. Cecchi, I. Olivotto, R. Gistri [et al.] // N Engl J Med. – 2003. –Vol. 349. - № 11. – Р. 1027-35.68. Timmer, S.A. Relation of coronary microvascular dysfunction in hypertrophiccardiomyopathy to contractile dysfunction independent from myocardial injury / S.A.Timmer, T. Germans, M.J. Gotte [et al.] // Am J Cardiol. – 2011. – Vol.107. - № 10. –P. 1522-812269.
Tyan, C.C. Stress hypoperfusion and tissue injury in hypertrophic cardiomyopathy:spatial characterization using high-resolution 3-tesla magnetic resonance imaging / C.C.Tyan, S. Armstrong, D. Scholl [et al.] // Circ Cardiovasc Imaging. – 2013.
– Vol. 6. -№2. – Р. 229-38.70. Bravo, P.E. Relationship of delayed enhancement by magnetic resonance tomyocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy/ P.E. Bravo, S.L. Zimmerman, H.C. Luo [et al.] // Circ Cardiovasc Imaging. – 2013. Vol. 6. -№ 2. – Р. 210-7.71. Yamano, M. Direct imaging of myocardial ischaemia with [18F]fluorodeoxyglucoseon exercise PET in hypertrophic cardiomyopathy/ M.
Yamano., T. Kawasaki., H.Sugihara // Heart. – 2009. - Vol. 95. - № 13. – Р. 1051.72. Dilsizian, V. Myocardial ischemia detected by thallium scintigraphy is frequentlyrelated to cardiac arrest and syncope in young patients with hypertrophiccardiomyopathy / V.
Dilsizian, R.O. Bonow, S.E. Epstein [et al.] // J Am Coll Cardiol. –1993. - Vol.22. - №3. - Р. 796–804.73. Sorajja, P. Prognostic utility of single-photon emission computed tomography inadult patients with hypertrophiccardiomyopathy / P. Sorajja, P. Chareonthaitawee, S.R.Ommen [et al.] // Am Heart J. – 2006.
– Vol. 151. - № 2. – P. 426-35.74. Romero-Farina , G. Do myocardial perfusion SPECT and radionuclide angiographystudies in adult patients with hypertrophic cardiomyopathy have prognosticimplications? / G. Romero-Farina., J. Candell-Riera, E. Galve // J Nucl Cardiol. – 2004.– Vol. 11. - № 5. – Р. 578-86.75. Nemes, A. Long-term prognostic value of coronary flow velocity reserve in patientswith hypertrophic cardiomyopathy: 9-year follow-up results from SZEGED study / A.Nemes, E. Balazs, O.I.
Soliman [et al.] // Heart Vessels. – 2009. - № 24. – Р. 352-6.76. Chan, R.H. Prognostic value of quantitative contrast-enhanced cardiovascularmagnetic resonance for the evaluation of sudden death risk in patients with hypertrophiccardiomyopathy / R.H, Chan, B.J.
Maron, I. Olivotto [et al.] // Circulation. – 2014. –Vol. 130. - № 6. – Р. 484-95.12377. Lee, K.H. Myocardial thallium defects in apical hypertrophic cardiomyopathy areassociated with a benign prognosis. Thallium defects in apical hypertrophy/ K.H. Lee,H.J. Jang, S.C.
Lee [et al.] // Int J Cardiovasc Imaging. – 2003. – Vol. 19. - № 5. – Р.381-8.78. Cannon, R.O. Myocardial metabolic, hemodynamic, and electrocardiographicsignificance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy /R.O. Cannon, V. Dilsizian, P.T. O’Gara [et al] // Circulation. – 1991. – Vol. 83. - №5 P.
1660–7.79. Udelson, J.E. Verapamil prevents silent myocardial perfusion abnormalities duringexercise in asymptomatic patients with hypertrophic cardiomyopathy / J.E. Udelson.,R.O. Bonow., P.T. O’Gara [et al] // Circulation. – 1989. - Vol. 79. - №5. – Р. 1052–60.80. Грамович, В.В. Количественная оценка перфузии миокарда с помощьюмагнитно-резонансной томографии / В.В. Грамович, В.Е Синицын, М.П.
Гордин[и др.] // Кардиология.- 2004.- № 8. - С. 4-12.81. Ларина, О.М. Диагностическое значение магнитно-резонансной томографиипри гипертрофии миокарда левого желудочка различного генеза. Литературныйобзор / О.М. Ларина // Вестник Российского научного центра рентгенорадиологииМинздрава России. – 2010. - № 10.82. Olivotto, I. Spectrum and clinical significance of systolic function and myocardialfibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy/ I. Olivotto, B.J. Maron, E. Appelbaum [et al.] // Am J Cardiol. – 2010. – Vol. 106.
- №2. – Р. 261–7.83. Sotgia, B. Spatial relationship between coronary microvascular dysfunction anddelayed contrast enhancement in patients with hypertrophic cardiomyopathy / B. Sotgia,R Sciagrà, I Olivotto [et al.] / J Nucl Med. – 2008. – Vol. 49. - № 7. – Р. 1090-6.84. Tezuka, D. Myocardial perfusion reserve quantified by cardiac magnetic resonanceimagingisassociatedwithlategadoliniumenhancementinhypertrophiccardiomyopathy / D. Tezuka, H. Kosuge, M. Terashima [et al.] // Heart Vessels. – 2018.Vol. 33. - № 5. – Р.
513-520.12485. Petersen, S.E. Evidence for microvascular dysfunction in hypertrophiccardiomyopathy: new insights from multiparametricmagnetic resonance imaging / S.E.Petersen, M. Jerosch-Herold, L.E. Hudsmith [et al.] // Circulation. – 2007. – Vol. 115. № 18. – Р. 2418-25.86. Sorajja, P. Adverse prognosis of patients with hypertrophic cardiomyopathy whohave epicardial coronary artery disease // P. Sorajja, S.R. Ommen, R.A. Nishimura [etal.] // Circulation.
– 2003. – Vol. 108. - № 19. – Р. 2342–8.87. Bourassa, M.G. Symptomatic myocardial bridges: overview of ischemicmechanisms and current diagnostic and treatment strategies / M.G. Bourassa, A.Butnaru, J. Lesperance [et al.] // J Am Coll Cardiol. – 2003. – Vol. 41. - № 3.
– Р. 351359.88. Schwarz, E.R. Functional, angiographic and intracoronary Doppler flowcharacteristics in symptomatic patients with myocardial bridging: effect of short-termintravenous beta-blocker medication / E.R. Schwarz, H.G. Klues, J. vom Dahl [et al.] //J Am Coll Cardiol. – 1996. – Vol. 27.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
